Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Lomustine-temozolomide vs. temozolomide bij glioblastoom met gemethyleerde MGMT-promotor
mrt 2019 | Neuro-oncologie